Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Cell

• Publication date

  2006-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CCR.2006.10.010PMID 17157790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ATM Engages Autodegradation of the E3 Ubiquitin Ligase COP1 After DNA Damage

  2006cited by this paper
• An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

  2006cited by this paper
• A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.

  2006cited by this paper
• Tumor suppression and normal aging in mice with constitutively high p53 activity.

  2006cited by this paper
• Gene‐specific mechanisms of p53 transcriptional control and prospects for cancer therapy

  2006cited by this paper
• Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.

  2006influential reference
• Regulation of the p53 transcriptional activity

  2006cited by this paper
• Binding of p53 to the Central Domain of Mdm2 Is Regulated by Phosphorylation*

  2006cited by this paper
• Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.

  2006influential reference
• Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death

  2006cited by this paper
• A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination.

  2006cited by this paper
• Dual-site regulation of MDM2 E3-ubiquitin ligase activity.

  2006cited by this paper
• p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53

  2005cited by this paper
• Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.

  2005influential reference
• Temporal dissection of p53 function in vitro and in vivo

  2005influential reference
• PUMA Couples the Nuclear and Cytoplasmic Proapoptotic Function of p53

  2005cited by this paper
• ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

  2005cited by this paper
• Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis.

  2005cited by this paper
• p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53.

  2005cited by this paper
• Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.

  2005cited by this paper
• Chemosensitization by antisense oligonucleotides targeting MDM2.

  2005influential reference
• Mdmx as an essential regulator of p53 activity.

  2005cited by this paper
• Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models

  2004cited by this paper
• Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis*♦

  2004cited by this paper
• Targeting the p53–MDM2 interaction to treat cancer

  2004cited by this paper
• Post-translational modification of p53 in tumorigenesis

  2004cited by this paper
• The ubiquitin ligase COP1 is a critical negative regulator of p53

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Phosphorylation of Serine 18 Regulates Distinct p53 Functions in Mice

  2004cited by this paper
• Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.

  2003cited by this paper
• Cell cycle regulatory functions of the human oncoprotein MDM2.

  2003cited by this paper
• mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation

  2003influential reference
• Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53*

  2002cited by this paper
• Tissue-specific induction of p53 targets in vivo.

  2002cited by this paper
• Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream.

  2002cited by this paper
• Mutual Dependence of MDM 2 and MDMX in Their Functional Inactivation of p 53 *

  2002cited by this paper
• Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage

  2002cited by this paper
• Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.

  2002cited by this paper
• Study of the cytotoxic effect of a peptidic inhibitor of the p53–hdm2 interaction in tumor cells

  2002cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Understanding the genotoxicity of tamoxifen?

  2001cited by this paper
• Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53

  2001cited by this paper
• A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

  2000cited by this paper
• Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice

  2000cited by this paper
• p53-independent functions of the p19(ARF) tumor suppressor.

  2000cited by this paper
• A novel MDM2 anti‐sense oligonucleotide has anti‐tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer

  2000cited by this paper
• p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53

  1999cited by this paper
• Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.

  1999cited by this paper
• The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53

  1998cited by this paper
• Nucleo‐cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein

  1998cited by this paper
• Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

  1997cited by this paper
• Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.

  1997influential reference
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• Repression of p53-mediated transcription by MDM2: a dual mechanism.

  1997cited by this paper
• Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/- mouse embryo fibroblasts.

  1996cited by this paper
• Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

  1995cited by this paper
• Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

  1995cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Clinical radiation pathology as applied to curative radiotherapy

  1968influential reference
• Theoretical Biology and Medical Modelling Open Access Targeting Mdm2 by the Small Molecule Rita: towards the Development of New Multi-target Drugs against Cancer Multi-target Drugsritacancer Treatmentblind Dockingmdm2p53 Tumor Suppressor

  year unknowncited by this paper

• Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer.

  2025cites this paper
• Targeting MDM2, RAS, and PCNA for cancer targeted therapy: pan-cancer approaches vs. cancer-specific strategies

  2025cites this paper
• Dependence on Mdm2 for Mdm4 inhibition of p53 activity.

  2025cites this paper
• Targeting therapeutic vulnerabilities in T-PLL.

  2024cites this paper
• Renal cancer: signaling pathways and advances in targeted therapies

  2024cites this paper
• Translating p53-based therapies for cancer into the clinic

  2024cites this paper
• p53/MDM2 signaling pathway in aging, senescence and tumorigenesis.

  2024cites this paper
• MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

  2024cites this paper
• SRBD1 Regulates the Cell Cycle, Apoptosis, and M2 Macrophage Polarization via the RPL11‐MDM2‐p53 Pathway in Glioma

  2024cites this paper
• Association of Vascular Endothelial Growth Factor (VEGF) and Mouse Model Minute 2 (MDM2) Polymorphisms With Diabetic Retinopathy in a Northwest Indian Population: A Case-Control Study

  2024cites this paper
• Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation

  2023cites this paper
• Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy

  2023cites this paper
• State of the Art of Pharmacological Activators of p53 in Ocular Malignancies

  2023cites this paper
• Rictor mediates p53 deactivation to facilitate the malignant transformation of hepatocytes and promote hepatocarcinogenesis

  2023cites this paper
• Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review

  2023cites this paper
• Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program

  2023cites this paper
• Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies.

  2023cites this paper
• In vivo RNA-seq and ChIP-seq analyses show an obligatory role for the C terminus of p53 in conferring tissue-specific radiation sensitivity

  2023cites this paper
• Recent advances in targeted therapy for pancreatic adenocarcinoma

  2023cites this paper
• A review for cancer treatment with mushroom metabolites through targeting mitochondrial signaling pathway: In vitro and in vivo evaluations, clinical studies and future prospects for mycomedicine.

  2023cites this paper
• MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation.

  2023cites this paper
• Partial p53 reactivation is sufficient to induce cancer regression

  2022cites this paper
• Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis

  2022cites this paper
• The Underestimated Role of the p53 Pathway in Renal Cancer

  2022cites this paper
• Alterations of the MDM2 C-terminus differentially impact its function in vivo.

  2022cites this paper
• It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy

  2022cites this paper
• The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review.

  2022cites this paper
• MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells

  2022cites this paper
• Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives

  2021cites this paper
• The Basally Expressed p53-Mediated Homeostatic Function

  2021cites this paper
• A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications.

  2021cites this paper
• What do we need to know and understand about p53 to improve its clinical value?

  2021cites this paper
• p53 partial loss-of-function mutations sensitize to chemotherapy

  2021cites this paper
• PRDX2 promotes the proliferation of colorectal cancer cells by increasing the ubiquitinated degradation of p53

  2021cites this paper
• Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141

  2021cites this paper
• p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR).

  2021cites this paper
• OTT_A_229577 185..197

  2020cites this paper
• p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo

  2020cites this paper
• FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.

  2020cites this paper
• p53 regulates its own expression by an intrinsic exoribonuclease activity through AU-rich elements

  2020cites this paper
• Genomic profiling of the transcription factor Zfp148 and its impact on the p53 pathway

  2020cites this paper
• MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation In Vivo

  2020cites this paper
• Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice

  2020cites this paper
• Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

  2020cites this paper
• Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and Aging

  2020cites this paper
• Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

  2020cites this paper
• Awakening the HSC: Dynamic Modeling of HSC Maintenance Unravels Regulation of the TP53 Pathway and Quiescence

  2020cites this paper
• The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis

  2020cites this paper
• The Roles of Ubiquitination Factor E4B (UBE4B) in the Postoperative Prognosis of Patients with Renal Cell Carcinoma and in Renal Tumor Cells Growth and Metastasis

  2020cites this paper
• MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression

  2019cites this paper
• A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize

  2019cites this paper
• The ER Fusion System in Mouse Models: A Reversible Switch

  2019cites this paper
• Akt Regulation of Mdm2-p53 Signaling in Cellular Stress Responses and Tumorigenesis

  2019cites this paper
• Inhibition of p53 inhibitors: progress, challenges and perspectives

  2019cites this paper
• Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression

  2019cites this paper
• Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity

  2018cites this paper
• Progress and challenges in Mesothelioma: From bench to bedside.

  2018cites this paper
• Inhibition of MDM 2 via Nutlin-3 A : A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM 2-Induced Inactivation of Wild-Type P 53

  2018cites this paper
• Glucose Metabolism and Carcinogenesis: The Impact of the Tumor Suppressor p53 Glucose Metabolism and Carcinogenesis: The Impact of the Tumor Suppressor p53

  2018cites this paper
• Glucose Metabolism and Carcinogenesis: The Impact of the Tumor Suppressor p53

  2018cites this paper
• Control of metabolism by p53 – Cancer and beyond

  2018cites this paper
• Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53

  2018cites this paper
• Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas

  2017cites this paper
• Mouse modelling of the MDM2/MDMX−p53 signalling axis

  2017influential citation
• New insights into regulation of p 53 protein degradation

  2017cites this paper
• In Vivo Discoveries in MDM2-Mediated p53 Regulation

  2017influential citation
• Relevance of the p53–MDM2 axis to aging

  2017cites this paper
• Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice

  2017cites this paper
• Targeting MDM4 Splicing in Cancers

  2017cites this paper
• Ubiquitin-specific peptidase 48 regulates Mdm2 protein levels independent of its deubiquitinase activity

  2017cites this paper
• The effect of inhibition of nucleotide synthesis on ribosome biogenesis and the induction of p53

  2017cites this paper
• The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis

  2017cites this paper
• miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma

  2017cites this paper
• Stem Cell Guardians - Old and New Perspectives in LSC Biology.

  2017cites this paper
• The p53 Independent Functions of Estrogen-Activated MDM2 in Cell Signaling and Mammary Architecture

  2017cites this paper
• Effective co-delivery of nutlin-3a and p53 genes via core-shell microparticles for disruption of MDM2-p53 interaction and reactivation of p53 in hepatocellular carcinoma.

  2017cites this paper
• Cardiac-specific ablation of the E3 ubiquitin ligase Mdm2 leads to oxidative stress, broad mitochondrial deficiency and early death

  2017cites this paper
• Postmitotic state of a cell as a challenge for regeneration: inner ear as a model

  2017cites this paper
• Physical and functional interactions of the tumor suppressor protein p53 with poly(ADP-ribose) polymerase-1 and its enzymatic product poly(ADP-ribose)

  2017cites this paper
• Indispensable role of Mdm2/p53 interaction during the embryonic and postnatal inner ear development

  2017cites this paper
• Mdm proteins: critical regulators of embryogenesis and homoeostasis

  2017cites this paper
• Podozyten-spezifischer Murine Double Minute (MDM) 2 Knockout führt zu fokal segmentaler Glomerulosklerose

  2017cites this paper
• Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53

  2016cites this paper
• Oncogenes and Tumor Suppressors p 53 Activity Dominates That of p 73 upon Mdm 4 Loss in Development and Tumorigenesis

  2016cites this paper
• MDM2 prevents spontaneous tubular epithelial cell death and acute kidney injury

  2016cites this paper
• Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors

  2016influential citation
• MDM2 oligomers: antagonizers of the guardian of the genome

  2016cites this paper
• Accumulation of p53 via down-regulation of UBE2D family genes is a critical pathway for cadmium-induced renal toxicity

  2016cites this paper
• Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

  2016cites this paper
• Rôle de deux suppresseurs de tumeurs TET2 et P53 dans un contexte hématopoïétique

  2016cites this paper
• The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression.

  2016influential citation
• microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma

  2016cites this paper
• L'oncogène Mdm2 : nouvelles fonctions et implications dans le métabolisme des cellules cancéreuses

  2016cites this paper
• An investigation into the roles of p53, Nodal/ Activin and fibroblast growth factor signalling in early heart development

  2016cites this paper
• Identification of EPSIN3 and CYSTATIN C as novel p53-inducible targets and their functional analysis

  2016influential citation
• MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

  2016cites this paper
• MDMX under stress: the MDMX-MDM2 complex as stress signals hub.

  2016cites this paper
• Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy

  2016influential citation
• Regulation of the p53 response and its relationship to cancer.

  2015cites this paper
• MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53

  2015cites this paper